Carboplatin News and Research

RSS
Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

University of Louisville researchers take a step forward in battle against lung cancer

University of Louisville researchers take a step forward in battle against lung cancer

New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Researchers test promising new breast cancer drugs

Researchers test promising new breast cancer drugs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.